Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc

Bullboard Posts

Comment by laffinatbaggieson Apr 04, 2017 5:45pm

428 Views

Post# 26076066

RE:below $10

laffinatbaggies wrote: This will be under $10 any day soon. It will go much lower from there. Bagholders will wish they sold above $10. There is still time, but it's running out.

Don't worry. Next stop is $8. After that $6. Enjoy baggies.

Bullboard Posts

Sirios Resource discovers visible gold in Quebec